,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pEx8UAE'}, 'Id': 'a0P2P000006pEx8UAE', 'Event_Date__c': '2016-02-09', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4CQAS'}, 'change': None}]",Feb 2016,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pEx9UAE'}, 'Id': 'a0P2P000006pEx9UAE', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArErQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'fs': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExAUAU'}, 'Id': 'a0P2P000006pExAUAU', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArEtQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2017', 'fs': 'Aug 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExCUAU'}, 'Id': 'a0P2P000006pExCUAU', 'Event_Date__c': '2017-08-10', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2017', 'Status_History__c': 'a132P000000ArJuQAK'}, 'change': None}, {'Summary': {'s': 'The Committee did not accept the recommendation from the December 2016 Nephrology Subcommittee meeting and noted that consideration of funding tolvaptan should follow the usual PHARMAC process of Medsafe approval and a funding application from the supplier for review by PTAC.', 'fs': 'The Committee did not accept the recommendation from the December 2016 Nephrology Subcommittee meeting and noted that consideration of funding tolvaptan should follow the usual PHARMAC process of Medsafe approval and a funding application from the supplier for review by PTAC.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2017', 'fs': 'Aug 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 August 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 August 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExDUAU'}, 'Id': 'a0P2P000006pExDUAU', 'Event_Date__c': '2017-08-10', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 August 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Deferred', 'Summary__c': 'The Committee did not accept the recommendation from the December 2016 Nephrology Subcommittee meeting and noted that consideration of funding tolvaptan should follow the usual PHARMAC process of Medsafe approval and a funding application from the supplier for review by PTAC.', 'Formatted_Date__c': 'Aug 2017', 'Status_History__c': 'a132P000000ArJvQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2017', 'fs': 'Sep 2017', 'change': None}, 'Event_Description': {'s': 'There is no Medsafe approved product of tolvaptan available in New Zealand. PHARMAC will revisit this application when a registered product is available.', 'fs': 'There is no Medsafe approved product of tolvaptan available in New Zealand. PHARMAC will revisit this application when a registered product is available.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExEUAU'}, 'Id': 'a0P2P000006pExEUAU', 'Event_Date__c': '2017-09-30', 'Event_Description__c': 'There is no Medsafe approved product of tolvaptan available in New Zealand. PHARMAC will revisit this application when a registered product is available.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2017', 'Status_History__c': 'a132P000000ArLXQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2019', 'fs': 'May 2019', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExFUAU'}, 'Id': 'a0P2P000006pExFUAU', 'Event_Date__c': '2019-05-27', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2019', 'Status_History__c': 'a132P000000ArgRQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExGUAU'}, 'Id': 'a0P2P000006pExGUAU', 'Event_Date__c': '2019-08-22', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000AriJQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that tolvaptan for the treatment of autosomal dominant polycystic chronic kidney disease (ADPKD) be listed with a high priority due to the high health need of this patient group and the evidence for a benefit from tolvaptan, subject to the following Special Authority criteria:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">TOLVAPTAN</b><span style=""font-size: 9pt;""> - Special Authority for Subsidy </span></p><p><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> - (autosomal dominant polycystic kidney disease) from a renal physician or on the recommendation of a renal physician. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an eGFR of between 25 and 65 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;""> at treatment initiation; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease is rapidly progressing, defined as either:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">a.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A decline in eGFR of greater than or equal to 5 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;""> within one-year; or </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">b.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">An average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2 </sup><span style=""font-size: 9pt;"">per year over a five-year period.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: Tolvaptan must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD, and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (liver function tests are required prior to tolvaptan initiation, monthly for the first 18 months and 3-monthly thereafter; concurrent monitoring for symptoms of possible liver injury is recommended). </span></p><p style=""text-align: justify;""><br></p><p><b style=""font-size: 9pt;"">Renewal</b><span style=""font-size: 9pt;""> - (autosomal dominant polycystic kidney disease) from a renal physician or on the recommendation of a renal physician. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has previously received tolvaptan for confirmed ADPKD; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate and the patient is benefitting from treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not developed end-stage renal disease (defined as an eGFR of less than 15 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;"">); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not undergone a kidney transplant.</span></p><p><span style=""font-size: 9pt;"">Note: Tolvaptan must be monitored under the supervision of physicians with expertise in managing ADPKD, and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (liver function tests are required monthly for the first 18 months and 3-monthly thereafter; concurrent monitoring for symptoms of possible liver injury is recommended).</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it would like to be informed of the outcome of PHARMAC’s economic modelling and considered that PHARMAC may need to prioritise different subgroups.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that tolvaptan for the treatment of autosomal dominant polycystic chronic kidney disease (ADPKD) be listed with a high priority due to the high health need of this patient group and the evidence for a benefit from tolvaptan, subject to the following Special Authority criteria:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">TOLVAPTAN</b><span style=""font-size: 9pt;""> - Special Authority for Subsidy </span></p><p><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> - (autosomal dominant polycystic kidney disease) from a renal physician or on the recommendation of a renal physician. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an eGFR of between 25 and 65 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;""> at treatment initiation; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease is rapidly progressing, defined as either:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">a.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A decline in eGFR of greater than or equal to 5 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;""> within one-year; or </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">b.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">An average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2 </sup><span style=""font-size: 9pt;"">per year over a five-year period.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: Tolvaptan must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD, and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (liver function tests are required prior to tolvaptan initiation, monthly for the first 18 months and 3-monthly thereafter; concurrent monitoring for symptoms of possible liver injury is recommended). </span></p><p style=""text-align: justify;""><br></p><p><b style=""font-size: 9pt;"">Renewal</b><span style=""font-size: 9pt;""> - (autosomal dominant polycystic kidney disease) from a renal physician or on the recommendation of a renal physician. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has previously received tolvaptan for confirmed ADPKD; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate and the patient is benefitting from treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not developed end-stage renal disease (defined as an eGFR of less than 15 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;"">); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not undergone a kidney transplant.</span></p><p><span style=""font-size: 9pt;"">Note: Tolvaptan must be monitored under the supervision of physicians with expertise in managing ADPKD, and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (liver function tests are required monthly for the first 18 months and 3-monthly thereafter; concurrent monitoring for symptoms of possible liver injury is recommended).</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it would like to be informed of the outcome of PHARMAC’s economic modelling and considered that PHARMAC may need to prioritise different subgroups.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p><i style=""font-size: 11pt;"">Background</i></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"" style=""color: windowtext;"">December 2016</a> the Nephrology Subcommittee reviewed a clinician application for tolvaptan for autosomal dominant polycystic chronic kidney disease (ADPKD), and that the Subcommittee had recommended that tolvaptan for patients with autosomal dominant polycystic kidney disease (ADPKD) be listed on the Pharmaceutical Schedule with a high priority if a registered product becomes available. The Committee noted that a new funding application for tolvaptan was received from Otsuka Australia Pharmaceutical Pty Ltd. in May 2018 and that tolvaptan was Medsafe-registered in May 2019.</p><p><i style=""font-size: 11pt;"">Discussion</i></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that ADPKD is a complex, progressive, systemic genetic condition characterised by an increase in the number and size of fluid-filled cysts in the kidney. Members noted that ADPKD usually appears in teens, progressively increases kidney size, decreases renal function (glomerular filtration rate; GFR) far more rapidly than the natural decline with increasing age, and leads to end stage renal disease (ESRD) before the age of 60 years. Members considered that ADPKD patients with chronic kidney disease (CKD) stage II and III will have progressive disease resulting in early death (in their 40s and 50s), with a pattern seen in other affected family members, although some patients may progress slowly such that ESRD may not prior to death from other causes. The Committee considered that patients with severe, progressing disease have an especially high health need. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are no disease-modifying treatments available for ADPKD and that standard of care in New Zealand is supportive care only. The Committee noted that patients with CKD will eventually require dialysis costing ~$70,000 per patient per year and may require kidney transplant costing ~$100,000 initially and then ~$13,000 per patient per year. Members noted that most kidney transplants in New Zealand are performed in Auckland, of which about 20% are pre-emptive for patients with GFR of 15 mL per min per 1.73m<sup>2</sup>. Members considered that kidney transplant would provide a significant benefit for patients on dialysis but would reduce life expectancy in patients who did not really need transplant (because of peri-operative mortality).</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the supplier estimate of approximately 2,000 patients in New Zealand with ADPKD, and noted that ADPKD contributes to about 5% of ESRD (<a href=""https://www.anzdata.org.au/wp-content/uploads/2018/11/c01_incidence_2017_v1.0_20181121.pdf"" target=""_blank"">ANZDATA Registry, 41<sup>st</sup> Report, 2018</a>). The Committee noted that in December 2016, the Nephrology Subcommittee considered that the incident population of patients with ADPKD in New Zealand is approximately 25 per year, and that Europeans aged between 18 and 50 years were predominantly affected, although the disease also affects Māori (rarely) and children (occasionally).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori patients with chronic kidney disease are marginalised by factors including delayed diagnosis, fear of dialysis, and lack of cultural and individual considerations during medical care and treatment decision-making (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC5253593"" target=""_blank"">Walker et al. BMJ Open. 2017;7:e013829</a>). The Committee considered that family and whānau of patients with CKD are impacted by the requirements and logistics of treatment, and the disease affects the social lives of affected individuals.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tolvaptan is a vasopressin V2 antagonist that inhibits vasopressin, resulting in increased urine output and reduced urine osmolality. The Committee noted that tolvaptan was approved by Medsafe in May 2019 and is indicated for slowing the progression of cyst development and renal insufficiency of ADPKD in adults with initial CKD stage 1 to 4 with evidence of rapidly progressing disease.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence for tolvaptan comes from two phase III, placebo-controlled, double-blind clinical trials: TEMPO 3:4 and REPRISE.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the primary publication from the randomised (2:1) TEMPO 3:4 trial, which investigated split-dose tolvaptan compared to placebo in 1,445 patients aged 18-50 years with ADPKD, total kidney volume (TKV) of at least 750 mL and estimated GFR (eGFR) of at least 60 mL per min per 1.73m<sup>2 </sup>(<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. N Engl J Med. 2012;367:2407-18</a>), and the results of a post-hoc analysis by CKD stage at baseline (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26912543"" target=""_blank"">Torres et al. Clin J Am Soc Nephrol. 2016:11;803-11</a><u style=""color: blue;"">),</u> both of which were reviewed by the Nephrology Subcommittee in December 2016. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary objective of the TEMPO 3:4 trial was to assess the change in TKV over 3 years and that the authors reported a 49.2% reduction in kidney growth rate with tolvaptan compared with placebo in the intention-to-treat population (<i>P</i>&lt;0.001), although the Committee considered that there was substantial variation in the values for TKV change in both patient groups (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). </p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the TEMPO 3:4 trial authors reported a statistically significant 26% difference in the annual change in eGFR (0.977 mL per min per per 1.73m<sup>2</sup>) between tolvaptan and placebo (95% CI 0.60 mL per min per 1.73m<sup>2</sup> to 1.36, <i>P</i>&lt;0.001) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>).\xa0</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there was preservation of kidney function (<i>P</i>&lt;0.001) and a lower risk of kidney pain requiring intervention (<i>P</i>=0.007) with tolvaptan compared to placebo (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). The Committee considered these outcomes were important for patients with ADPKD especially those with kidney pain, which can be extreme in ESRD. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the TEMPO 3:4 trial included patients with CKD stages 1 to 3 and considered that the proportion of patients with stage 3b CKD (eGFR 30 to 44; N = 42, 3%) was small (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). The Committee considered that the trial eligibility criteria specifically selected a patient population with rapidly progressing disease. The Committee considered that the 3-year treatment duration was a limitation of the study. The Committee also noted the following published evidence from the TEMPO 3:4 trial:</p><p>1.12.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28379536"" target=""_blank"">Torres et al. Nephrol Dial Transplant. 2018:33;477-489</a> - TEMPO 4:4 open-label extension trial (additional 2 year follow up of TEMPO 3:4)</p><p>1.12.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=tempo+PROPKD"" target=""_blank"">Cornec-Le Gall et al. Nephrol Dial Transplant. 2018:33;645-52</a> - TEMPO 3:4 post-hoc analysis of PROPKD score</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that severe (grade 3 and higher) hepatic dysfunction occurred in 2-4% of TEMPO 4:4 trial patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28379536"" target=""_blank"">Torres et al. 2018</a>). The Committee noted that major known adverse effects of tolvaptan are idiosyncratic hepatic toxicity with hepatic dysfunction occurring 3 to 18 months after treatment starts, and aquaresis-related adverse events (Source: <a href=""https://www.medsafe.govt.nz/profs/Datasheet/j/jinarctabcomb.pdf"" target=""_blank"">Medsafe Data Sheet, May 2019</a>).</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of the randomised (1:1) REPRISE trial, which investigated split-dose tolvaptan compared to placebo in 1,370 patients with ADPKD aged 18-55 years with eGFR between 25 and 65 mL per min per 1.73m<sup>2</sup> and aged 56 to 65 years with eGFR between 25 and 44 mL per min per 1.73m<sup>2</sup> (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. N Engl J Med. 2017:377;1930-42</a><u style=""color: blue;"">). </u></p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that REPRISE provided further data on tolvaptan treatment and included patients over 50 years of age (which was considered important by the Nephrology Subcommittee, although it included only a small proportion (~8%) of non-Caucasian patients). The Committee noted that the trial eligibility criteria targeted patients with severe disease, and considered that the trial patient group would equate to approximately a quarter of the patient population with ADPKD due to variation in disease progression and therefore ~75% of patients with less severe disease were excluded from the trial. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary objective of the REPRISE trial was to assess the change in renal function (eGFR) from baseline to follow-up, and that the authors had reported a statistically significant 30% difference in the change in eGFR (1.27 mL per min per per 1.73m<sup>2</sup>) between tolvaptan and placebo at 1 year (95% CI 0.86 mL per min per 1.73m<sup>2</sup> to 1.68, <i>P</i>&lt;0.001) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. 2017</a><u style=""color: blue;"">).</u></p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that most participants adhered to the trial treatment, and discontinuation due to adverse events (AEs) occurred in 9.5% of patients who received tolvaptan compared with 2.2% of patients who received placebo (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. 2017</a><u style=""color: blue;"">). </u>The Committee noted that serious hepatic AEs were reported in 4.6% of patients who received tolvaptan compared to 0.6% of patients who received placebo in the REPRISE trial. The Committee noted that these events were not fatal and the liver effects were reversed after stopping treatment.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the supplier had stated tolvaptan provides one extra year of kidney life for every four years of treatment, and considered that this would be through delayed time to start of dialysis.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the TEMPO 3:4, TEMPO 4:4 and REPRISE trials provide no evidence for tolvaptan use in children with ADPKD, and that there is limited inclusion of non-Caucasian patients with ADPKD. Members considered there is limited long-term data for delayed dialysis and kidney transplant. The Committee considered that tolvaptan provides a benefit for patients with ADPKD and CKD stage 2 or 3 disease, although this effect is difficult to quantify. </p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of an exploratory analysis modelling the long-term benefits of tolvaptan on renal function decline in ADPKD to predict natural disease progression with renal function decline based on that of the TEMPO 3:4 trial, which was compared with the TEMPO 4:4 and REPRISE trials (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=31014270"" target=""_blank"">Bennett et al. BMC Nephrol. 2019;20:136</a>). The Committee noted that the analysis of simulated patients matched to the TEMPO 3:4 trial population predicts a delay of 5 years to mean age of ESRD onset compared with natural disease progression, and that subgroup analysis suggests delays of 6.6 years for CKD stage 1, 4.7 years for CKD stage 2 and 2.7 years for CKD stage 3. The Committee considered that treatment given at CKD stage 1 would provide the most benefit of delayed ESRD, and that long-term benefit is dependent on a particular patient’s disease status at baseline and trajectory of disease progression.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the treatment paradigm and dosing schedule proposed by the supplier for tolvaptan treatment would require considerable input from primary care, and there is a need to monitor patients for hepatic adverse effects. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that funding treatment with tolvaptan may improve equity of access to treatment for ADPKD, noting that there are challenges with patient access to dialysis e.g. lack of cultural and individual considerations with the needs of Māori, or transplant e.g. kidney availability).</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier application concentrates on the most cost-effective patient population (CKD stages 2 and 3) with a focus on those with most severe disease, which results in a conservative Cost-Utility Analysis (CUA) from the supplier. However, the Committee considered that this approach excludes patients with CKD stage 1, whose disease would progress slowly but who would benefit from an improvement in years, and thus treatment may be relatively cost-effective for them too (subject to further analysis). The Committee also noted, however, that analysis would need to include improvements (and consequences) in blood pressure associated with slower kidney function loss, and other pathology e.g. diabetes. </p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, under the supplier-proposed criteria, about 530 patients per year with ADPKD may be able to benefit from treatment with tolvaptan and delayed dialysis. The Committee considered that the supplier-proposed patient group is too narrow and excludes CKD stage 1 patients who may benefit, and that the access criteria should therefore align with the patient population from the clinical trial evidence. The Committee considered that PHARMAC could further investigate the number of New Zealand patients who may benefit from treatment with tolvaptan.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the costs of dialysis (which would be postponed rather than not required) would generally be balanced against the cost of treatment with tolvaptan, although the rate of ADPKD progression is highly variable and some patients may have less benefit in terms of time until dialysis is required. Members considered that on average, a patient with GFR of ~45 mL per min per 1.73m<sup>2 </sup>may benefit from delaying ESRD by 4.5 years, with a total of about 12 years on tolvaptan treatment. </p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tolvaptan should be funded due to the high health need of this patient group and the evidence for a benefit from tolvaptan. The Committee considered that it would like to be informed of the outcome of PHARMAC’s economic modelling and considered that PHARMAC may need to prioritise different subgroups. Members considered a recent study of changes in incidence and survival of ESRD due to PKD in Australia and New Zealand (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28212688"" target=""_blank"">Fernando et al. Popul Health Metr. 2017;15:7</a>), transplant rates for Auckland and rates of deterioration from the REPRISE study would provide useful data for economic modelling.</p>', 'fs': '<p><i style=""font-size: 11pt;"">Background</i></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"" style=""color: windowtext;"">December 2016</a> the Nephrology Subcommittee reviewed a clinician application for tolvaptan for autosomal dominant polycystic chronic kidney disease (ADPKD), and that the Subcommittee had recommended that tolvaptan for patients with autosomal dominant polycystic kidney disease (ADPKD) be listed on the Pharmaceutical Schedule with a high priority if a registered product becomes available. The Committee noted that a new funding application for tolvaptan was received from Otsuka Australia Pharmaceutical Pty Ltd. in May 2018 and that tolvaptan was Medsafe-registered in May 2019.</p><p><i style=""font-size: 11pt;"">Discussion</i></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that ADPKD is a complex, progressive, systemic genetic condition characterised by an increase in the number and size of fluid-filled cysts in the kidney. Members noted that ADPKD usually appears in teens, progressively increases kidney size, decreases renal function (glomerular filtration rate; GFR) far more rapidly than the natural decline with increasing age, and leads to end stage renal disease (ESRD) before the age of 60 years. Members considered that ADPKD patients with chronic kidney disease (CKD) stage II and III will have progressive disease resulting in early death (in their 40s and 50s), with a pattern seen in other affected family members, although some patients may progress slowly such that ESRD may not prior to death from other causes. The Committee considered that patients with severe, progressing disease have an especially high health need. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are no disease-modifying treatments available for ADPKD and that standard of care in New Zealand is supportive care only. The Committee noted that patients with CKD will eventually require dialysis costing ~$70,000 per patient per year and may require kidney transplant costing ~$100,000 initially and then ~$13,000 per patient per year. Members noted that most kidney transplants in New Zealand are performed in Auckland, of which about 20% are pre-emptive for patients with GFR of 15 mL per min per 1.73m<sup>2</sup>. Members considered that kidney transplant would provide a significant benefit for patients on dialysis but would reduce life expectancy in patients who did not really need transplant (because of peri-operative mortality).</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the supplier estimate of approximately 2,000 patients in New Zealand with ADPKD, and noted that ADPKD contributes to about 5% of ESRD (<a href=""https://www.anzdata.org.au/wp-content/uploads/2018/11/c01_incidence_2017_v1.0_20181121.pdf"" target=""_blank"">ANZDATA Registry, 41<sup>st</sup> Report, 2018</a>). The Committee noted that in December 2016, the Nephrology Subcommittee considered that the incident population of patients with ADPKD in New Zealand is approximately 25 per year, and that Europeans aged between 18 and 50 years were predominantly affected, although the disease also affects Māori (rarely) and children (occasionally).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori patients with chronic kidney disease are marginalised by factors including delayed diagnosis, fear of dialysis, and lack of cultural and individual considerations during medical care and treatment decision-making (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC5253593"" target=""_blank"">Walker et al. BMJ Open. 2017;7:e013829</a>). The Committee considered that family and whānau of patients with CKD are impacted by the requirements and logistics of treatment, and the disease affects the social lives of affected individuals.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tolvaptan is a vasopressin V2 antagonist that inhibits vasopressin, resulting in increased urine output and reduced urine osmolality. The Committee noted that tolvaptan was approved by Medsafe in May 2019 and is indicated for slowing the progression of cyst development and renal insufficiency of ADPKD in adults with initial CKD stage 1 to 4 with evidence of rapidly progressing disease.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence for tolvaptan comes from two phase III, placebo-controlled, double-blind clinical trials: TEMPO 3:4 and REPRISE.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the primary publication from the randomised (2:1) TEMPO 3:4 trial, which investigated split-dose tolvaptan compared to placebo in 1,445 patients aged 18-50 years with ADPKD, total kidney volume (TKV) of at least 750 mL and estimated GFR (eGFR) of at least 60 mL per min per 1.73m<sup>2 </sup>(<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. N Engl J Med. 2012;367:2407-18</a>), and the results of a post-hoc analysis by CKD stage at baseline (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26912543"" target=""_blank"">Torres et al. Clin J Am Soc Nephrol. 2016:11;803-11</a><u style=""color: blue;"">),</u> both of which were reviewed by the Nephrology Subcommittee in December 2016. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary objective of the TEMPO 3:4 trial was to assess the change in TKV over 3 years and that the authors reported a 49.2% reduction in kidney growth rate with tolvaptan compared with placebo in the intention-to-treat population (<i>P</i>&lt;0.001), although the Committee considered that there was substantial variation in the values for TKV change in both patient groups (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). </p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the TEMPO 3:4 trial authors reported a statistically significant 26% difference in the annual change in eGFR (0.977 mL per min per per 1.73m<sup>2</sup>) between tolvaptan and placebo (95% CI 0.60 mL per min per 1.73m<sup>2</sup> to 1.36, <i>P</i>&lt;0.001) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>).\xa0</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there was preservation of kidney function (<i>P</i>&lt;0.001) and a lower risk of kidney pain requiring intervention (<i>P</i>=0.007) with tolvaptan compared to placebo (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). The Committee considered these outcomes were important for patients with ADPKD especially those with kidney pain, which can be extreme in ESRD. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the TEMPO 3:4 trial included patients with CKD stages 1 to 3 and considered that the proportion of patients with stage 3b CKD (eGFR 30 to 44; N = 42, 3%) was small (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). The Committee considered that the trial eligibility criteria specifically selected a patient population with rapidly progressing disease. The Committee considered that the 3-year treatment duration was a limitation of the study. The Committee also noted the following published evidence from the TEMPO 3:4 trial:</p><p>1.12.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28379536"" target=""_blank"">Torres et al. Nephrol Dial Transplant. 2018:33;477-489</a> - TEMPO 4:4 open-label extension trial (additional 2 year follow up of TEMPO 3:4)</p><p>1.12.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=tempo+PROPKD"" target=""_blank"">Cornec-Le Gall et al. Nephrol Dial Transplant. 2018:33;645-52</a> - TEMPO 3:4 post-hoc analysis of PROPKD score</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that severe (grade 3 and higher) hepatic dysfunction occurred in 2-4% of TEMPO 4:4 trial patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28379536"" target=""_blank"">Torres et al. 2018</a>). The Committee noted that major known adverse effects of tolvaptan are idiosyncratic hepatic toxicity with hepatic dysfunction occurring 3 to 18 months after treatment starts, and aquaresis-related adverse events (Source: <a href=""https://www.medsafe.govt.nz/profs/Datasheet/j/jinarctabcomb.pdf"" target=""_blank"">Medsafe Data Sheet, May 2019</a>).</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of the randomised (1:1) REPRISE trial, which investigated split-dose tolvaptan compared to placebo in 1,370 patients with ADPKD aged 18-55 years with eGFR between 25 and 65 mL per min per 1.73m<sup>2</sup> and aged 56 to 65 years with eGFR between 25 and 44 mL per min per 1.73m<sup>2</sup> (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. N Engl J Med. 2017:377;1930-42</a><u style=""color: blue;"">). </u></p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that REPRISE provided further data on tolvaptan treatment and included patients over 50 years of age (which was considered important by the Nephrology Subcommittee, although it included only a small proportion (~8%) of non-Caucasian patients). The Committee noted that the trial eligibility criteria targeted patients with severe disease, and considered that the trial patient group would equate to approximately a quarter of the patient population with ADPKD due to variation in disease progression and therefore ~75% of patients with less severe disease were excluded from the trial. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary objective of the REPRISE trial was to assess the change in renal function (eGFR) from baseline to follow-up, and that the authors had reported a statistically significant 30% difference in the change in eGFR (1.27 mL per min per per 1.73m<sup>2</sup>) between tolvaptan and placebo at 1 year (95% CI 0.86 mL per min per 1.73m<sup>2</sup> to 1.68, <i>P</i>&lt;0.001) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. 2017</a><u style=""color: blue;"">).</u></p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that most participants adhered to the trial treatment, and discontinuation due to adverse events (AEs) occurred in 9.5% of patients who received tolvaptan compared with 2.2% of patients who received placebo (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. 2017</a><u style=""color: blue;"">). </u>The Committee noted that serious hepatic AEs were reported in 4.6% of patients who received tolvaptan compared to 0.6% of patients who received placebo in the REPRISE trial. The Committee noted that these events were not fatal and the liver effects were reversed after stopping treatment.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the supplier had stated tolvaptan provides one extra year of kidney life for every four years of treatment, and considered that this would be through delayed time to start of dialysis.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the TEMPO 3:4, TEMPO 4:4 and REPRISE trials provide no evidence for tolvaptan use in children with ADPKD, and that there is limited inclusion of non-Caucasian patients with ADPKD. Members considered there is limited long-term data for delayed dialysis and kidney transplant. The Committee considered that tolvaptan provides a benefit for patients with ADPKD and CKD stage 2 or 3 disease, although this effect is difficult to quantify. </p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of an exploratory analysis modelling the long-term benefits of tolvaptan on renal function decline in ADPKD to predict natural disease progression with renal function decline based on that of the TEMPO 3:4 trial, which was compared with the TEMPO 4:4 and REPRISE trials (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=31014270"" target=""_blank"">Bennett et al. BMC Nephrol. 2019;20:136</a>). The Committee noted that the analysis of simulated patients matched to the TEMPO 3:4 trial population predicts a delay of 5 years to mean age of ESRD onset compared with natural disease progression, and that subgroup analysis suggests delays of 6.6 years for CKD stage 1, 4.7 years for CKD stage 2 and 2.7 years for CKD stage 3. The Committee considered that treatment given at CKD stage 1 would provide the most benefit of delayed ESRD, and that long-term benefit is dependent on a particular patient’s disease status at baseline and trajectory of disease progression.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the treatment paradigm and dosing schedule proposed by the supplier for tolvaptan treatment would require considerable input from primary care, and there is a need to monitor patients for hepatic adverse effects. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that funding treatment with tolvaptan may improve equity of access to treatment for ADPKD, noting that there are challenges with patient access to dialysis e.g. lack of cultural and individual considerations with the needs of Māori, or transplant e.g. kidney availability).</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier application concentrates on the most cost-effective patient population (CKD stages 2 and 3) with a focus on those with most severe disease, which results in a conservative Cost-Utility Analysis (CUA) from the supplier. However, the Committee considered that this approach excludes patients with CKD stage 1, whose disease would progress slowly but who would benefit from an improvement in years, and thus treatment may be relatively cost-effective for them too (subject to further analysis). The Committee also noted, however, that analysis would need to include improvements (and consequences) in blood pressure associated with slower kidney function loss, and other pathology e.g. diabetes. </p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, under the supplier-proposed criteria, about 530 patients per year with ADPKD may be able to benefit from treatment with tolvaptan and delayed dialysis. The Committee considered that the supplier-proposed patient group is too narrow and excludes CKD stage 1 patients who may benefit, and that the access criteria should therefore align with the patient population from the clinical trial evidence. The Committee considered that PHARMAC could further investigate the number of New Zealand patients who may benefit from treatment with tolvaptan.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the costs of dialysis (which would be postponed rather than not required) would generally be balanced against the cost of treatment with tolvaptan, although the rate of ADPKD progression is highly variable and some patients may have less benefit in terms of time until dialysis is required. Members considered that on average, a patient with GFR of ~45 mL per min per 1.73m<sup>2 </sup>may benefit from delaying ESRD by 4.5 years, with a total of about 12 years on tolvaptan treatment. </p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tolvaptan should be funded due to the high health need of this patient group and the evidence for a benefit from tolvaptan. The Committee considered that it would like to be informed of the outcome of PHARMAC’s economic modelling and considered that PHARMAC may need to prioritise different subgroups. Members considered a recent study of changes in incidence and survival of ESRD due to PKD in Australia and New Zealand (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28212688"" target=""_blank"">Fernando et al. Popul Health Metr. 2017;15:7</a>), transplant rates for Auckland and rates of deterioration from the REPRISE study would provide useful data for economic modelling.</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for tolvaptan for the treatment of autosomal dominant polycystic chronic kidney disease (ADPKD) from Otsuka Australia Pharmaceutical Pty Ltd. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for tolvaptan for the treatment of autosomal dominant polycystic chronic kidney disease (ADPKD) from Otsuka Australia Pharmaceutical Pty Ltd. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2019', 'fs': 'Nov 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExHUAU'}, 'Id': 'a0P2P000006pExHUAU', 'Event_Date__c': '2019-11-22', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 23 August 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Nov 2019', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that tolvaptan for the treatment of autosomal dominant polycystic chronic kidney disease (ADPKD) be listed with a high priority due to the high health need of this patient group and the evidence for a benefit from tolvaptan, subject to the following Special Authority criteria:</p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">TOLVAPTAN</b><span style=""font-size: 9pt;""> - Special Authority for Subsidy </span></p><p><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> - (autosomal dominant polycystic kidney disease) from a renal physician or on the recommendation of a renal physician. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a confirmed diagnosis of autosomal dominant polycystic kidney disease (ADPKD); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an eGFR of between 25 and 65 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;""> at treatment initiation; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s disease is rapidly progressing, defined as either:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">a.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A decline in eGFR of greater than or equal to 5 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;""> within one-year; or </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">b.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">An average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2 </sup><span style=""font-size: 9pt;"">per year over a five-year period.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: Tolvaptan must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD, and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (liver function tests are required prior to tolvaptan initiation, monthly for the first 18 months and 3-monthly thereafter; concurrent monitoring for symptoms of possible liver injury is recommended). </span></p><p style=""text-align: justify;""><br></p><p><b style=""font-size: 9pt;"">Renewal</b><span style=""font-size: 9pt;""> - (autosomal dominant polycystic kidney disease) from a renal physician or on the recommendation of a renal physician. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has previously received tolvaptan for confirmed ADPKD; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The treatment remains appropriate and the patient is benefitting from treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not developed end-stage renal disease (defined as an eGFR of less than 15 mL/min/1.73 m</span><sup style=""font-size: 9pt;"">2</sup><span style=""font-size: 9pt;"">); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has not undergone a kidney transplant.</span></p><p><span style=""font-size: 9pt;"">Note: Tolvaptan must be monitored under the supervision of physicians with expertise in managing ADPKD, and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements (liver function tests are required monthly for the first 18 months and 3-monthly thereafter; concurrent monitoring for symptoms of possible liver injury is recommended).</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that it would like to be informed of the outcome of PHARMAC’s economic modelling and considered that PHARMAC may need to prioritise different subgroups.\xa0</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee reviewed the application for tolvaptan for the treatment of autosomal dominant polycystic chronic kidney disease (ADPKD) from Otsuka Australia Pharmaceutical Pty Ltd. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><i style=""font-size: 11pt;"">Background</i></p><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"" style=""color: windowtext;"">December 2016</a> the Nephrology Subcommittee reviewed a clinician application for tolvaptan for autosomal dominant polycystic chronic kidney disease (ADPKD), and that the Subcommittee had recommended that tolvaptan for patients with autosomal dominant polycystic kidney disease (ADPKD) be listed on the Pharmaceutical Schedule with a high priority if a registered product becomes available. The Committee noted that a new funding application for tolvaptan was received from Otsuka Australia Pharmaceutical Pty Ltd. in May 2018 and that tolvaptan was Medsafe-registered in May 2019.</p><p><i style=""font-size: 11pt;"">Discussion</i></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that ADPKD is a complex, progressive, systemic genetic condition characterised by an increase in the number and size of fluid-filled cysts in the kidney. Members noted that ADPKD usually appears in teens, progressively increases kidney size, decreases renal function (glomerular filtration rate; GFR) far more rapidly than the natural decline with increasing age, and leads to end stage renal disease (ESRD) before the age of 60 years. Members considered that ADPKD patients with chronic kidney disease (CKD) stage II and III will have progressive disease resulting in early death (in their 40s and 50s), with a pattern seen in other affected family members, although some patients may progress slowly such that ESRD may not prior to death from other causes. The Committee considered that patients with severe, progressing disease have an especially high health need. </p><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that there are no disease-modifying treatments available for ADPKD and that standard of care in New Zealand is supportive care only. The Committee noted that patients with CKD will eventually require dialysis costing ~$70,000 per patient per year and may require kidney transplant costing ~$100,000 initially and then ~$13,000 per patient per year. Members noted that most kidney transplants in New Zealand are performed in Auckland, of which about 20% are pre-emptive for patients with GFR of 15 mL per min per 1.73m<sup>2</sup>. Members considered that kidney transplant would provide a significant benefit for patients on dialysis but would reduce life expectancy in patients who did not really need transplant (because of peri-operative mortality).</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the supplier estimate of approximately 2,000 patients in New Zealand with ADPKD, and noted that ADPKD contributes to about 5% of ESRD (<a href=""https://www.anzdata.org.au/wp-content/uploads/2018/11/c01_incidence_2017_v1.0_20181121.pdf"" target=""_blank"">ANZDATA Registry, 41<sup>st</sup> Report, 2018</a>). The Committee noted that in December 2016, the Nephrology Subcommittee considered that the incident population of patients with ADPKD in New Zealand is approximately 25 per year, and that Europeans aged between 18 and 50 years were predominantly affected, although the disease also affects Māori (rarely) and children (occasionally).</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that Māori patients with chronic kidney disease are marginalised by factors including delayed diagnosis, fear of dialysis, and lack of cultural and individual considerations during medical care and treatment decision-making (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC5253593"" target=""_blank"">Walker et al. BMJ Open. 2017;7:e013829</a>). The Committee considered that family and whānau of patients with CKD are impacted by the requirements and logistics of treatment, and the disease affects the social lives of affected individuals.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that tolvaptan is a vasopressin V2 antagonist that inhibits vasopressin, resulting in increased urine output and reduced urine osmolality. The Committee noted that tolvaptan was approved by Medsafe in May 2019 and is indicated for slowing the progression of cyst development and renal insufficiency of ADPKD in adults with initial CKD stage 1 to 4 with evidence of rapidly progressing disease.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the evidence for tolvaptan comes from two phase III, placebo-controlled, double-blind clinical trials: TEMPO 3:4 and REPRISE.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the primary publication from the randomised (2:1) TEMPO 3:4 trial, which investigated split-dose tolvaptan compared to placebo in 1,445 patients aged 18-50 years with ADPKD, total kidney volume (TKV) of at least 750 mL and estimated GFR (eGFR) of at least 60 mL per min per 1.73m<sup>2 </sup>(<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. N Engl J Med. 2012;367:2407-18</a>), and the results of a post-hoc analysis by CKD stage at baseline (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26912543"" target=""_blank"">Torres et al. Clin J Am Soc Nephrol. 2016:11;803-11</a><u style=""color: blue;"">),</u> both of which were reviewed by the Nephrology Subcommittee in December 2016. </p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary objective of the TEMPO 3:4 trial was to assess the change in TKV over 3 years and that the authors reported a 49.2% reduction in kidney growth rate with tolvaptan compared with placebo in the intention-to-treat population (<i>P</i>&lt;0.001), although the Committee considered that there was substantial variation in the values for TKV change in both patient groups (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). </p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the TEMPO 3:4 trial authors reported a statistically significant 26% difference in the annual change in eGFR (0.977 mL per min per per 1.73m<sup>2</sup>) between tolvaptan and placebo (95% CI 0.60 mL per min per 1.73m<sup>2</sup> to 1.36, <i>P</i>&lt;0.001) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>).\xa0</p><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted there was preservation of kidney function (<i>P</i>&lt;0.001) and a lower risk of kidney pain requiring intervention (<i>P</i>=0.007) with tolvaptan compared to placebo (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). The Committee considered these outcomes were important for patients with ADPKD especially those with kidney pain, which can be extreme in ESRD. </p><p>1.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the TEMPO 3:4 trial included patients with CKD stages 1 to 3 and considered that the proportion of patients with stage 3b CKD (eGFR 30 to 44; N = 42, 3%) was small (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23121377"" target=""_blank"">Torres et al. 2012</a>). The Committee considered that the trial eligibility criteria specifically selected a patient population with rapidly progressing disease. The Committee considered that the 3-year treatment duration was a limitation of the study. The Committee also noted the following published evidence from the TEMPO 3:4 trial:</p><p>1.12.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/28379536"" target=""_blank"">Torres et al. Nephrol Dial Transplant. 2018:33;477-489</a> - TEMPO 4:4 open-label extension trial (additional 2 year follow up of TEMPO 3:4)</p><p>1.12.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=tempo+PROPKD"" target=""_blank"">Cornec-Le Gall et al. Nephrol Dial Transplant. 2018:33;645-52</a> - TEMPO 3:4 post-hoc analysis of PROPKD score</p><p>1.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that severe (grade 3 and higher) hepatic dysfunction occurred in 2-4% of TEMPO 4:4 trial patients (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28379536"" target=""_blank"">Torres et al. 2018</a>). The Committee noted that major known adverse effects of tolvaptan are idiosyncratic hepatic toxicity with hepatic dysfunction occurring 3 to 18 months after treatment starts, and aquaresis-related adverse events (Source: <a href=""https://www.medsafe.govt.nz/profs/Datasheet/j/jinarctabcomb.pdf"" target=""_blank"">Medsafe Data Sheet, May 2019</a>).</p><p>1.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of the randomised (1:1) REPRISE trial, which investigated split-dose tolvaptan compared to placebo in 1,370 patients with ADPKD aged 18-55 years with eGFR between 25 and 65 mL per min per 1.73m<sup>2</sup> and aged 56 to 65 years with eGFR between 25 and 44 mL per min per 1.73m<sup>2</sup> (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. N Engl J Med. 2017:377;1930-42</a><u style=""color: blue;"">). </u></p><p>1.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that REPRISE provided further data on tolvaptan treatment and included patients over 50 years of age (which was considered important by the Nephrology Subcommittee, although it included only a small proportion (~8%) of non-Caucasian patients). The Committee noted that the trial eligibility criteria targeted patients with severe disease, and considered that the trial patient group would equate to approximately a quarter of the patient population with ADPKD due to variation in disease progression and therefore ~75% of patients with less severe disease were excluded from the trial. </p><p>1.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the primary objective of the REPRISE trial was to assess the change in renal function (eGFR) from baseline to follow-up, and that the authors had reported a statistically significant 30% difference in the change in eGFR (1.27 mL per min per per 1.73m<sup>2</sup>) between tolvaptan and placebo at 1 year (95% CI 0.86 mL per min per 1.73m<sup>2</sup> to 1.68, <i>P</i>&lt;0.001) (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. 2017</a><u style=""color: blue;"">).</u></p><p>1.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that most participants adhered to the trial treatment, and discontinuation due to adverse events (AEs) occurred in 9.5% of patients who received tolvaptan compared with 2.2% of patients who received placebo (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29105594"" target=""_blank"">Torres et al. 2017</a><u style=""color: blue;"">). </u>The Committee noted that serious hepatic AEs were reported in 4.6% of patients who received tolvaptan compared to 0.6% of patients who received placebo in the REPRISE trial. The Committee noted that these events were not fatal and the liver effects were reversed after stopping treatment.</p><p>1.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the supplier had stated tolvaptan provides one extra year of kidney life for every four years of treatment, and considered that this would be through delayed time to start of dialysis.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the TEMPO 3:4, TEMPO 4:4 and REPRISE trials provide no evidence for tolvaptan use in children with ADPKD, and that there is limited inclusion of non-Caucasian patients with ADPKD. Members considered there is limited long-term data for delayed dialysis and kidney transplant. The Committee considered that tolvaptan provides a benefit for patients with ADPKD and CKD stage 2 or 3 disease, although this effect is difficult to quantify. </p><p>1.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the results of an exploratory analysis modelling the long-term benefits of tolvaptan on renal function decline in ADPKD to predict natural disease progression with renal function decline based on that of the TEMPO 3:4 trial, which was compared with the TEMPO 4:4 and REPRISE trials (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=31014270"" target=""_blank"">Bennett et al. BMC Nephrol. 2019;20:136</a>). The Committee noted that the analysis of simulated patients matched to the TEMPO 3:4 trial population predicts a delay of 5 years to mean age of ESRD onset compared with natural disease progression, and that subgroup analysis suggests delays of 6.6 years for CKD stage 1, 4.7 years for CKD stage 2 and 2.7 years for CKD stage 3. The Committee considered that treatment given at CKD stage 1 would provide the most benefit of delayed ESRD, and that long-term benefit is dependent on a particular patient’s disease status at baseline and trajectory of disease progression.</p><p>1.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the treatment paradigm and dosing schedule proposed by the supplier for tolvaptan treatment would require considerable input from primary care, and there is a need to monitor patients for hepatic adverse effects. </p><p>1.22.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that funding treatment with tolvaptan may improve equity of access to treatment for ADPKD, noting that there are challenges with patient access to dialysis e.g. lack of cultural and individual considerations with the needs of Māori, or transplant e.g. kidney availability).</p><p>1.23.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that the supplier application concentrates on the most cost-effective patient population (CKD stages 2 and 3) with a focus on those with most severe disease, which results in a conservative Cost-Utility Analysis (CUA) from the supplier. However, the Committee considered that this approach excludes patients with CKD stage 1, whose disease would progress slowly but who would benefit from an improvement in years, and thus treatment may be relatively cost-effective for them too (subject to further analysis). The Committee also noted, however, that analysis would need to include improvements (and consequences) in blood pressure associated with slower kidney function loss, and other pathology e.g. diabetes. </p><p>1.24.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that, under the supplier-proposed criteria, about 530 patients per year with ADPKD may be able to benefit from treatment with tolvaptan and delayed dialysis. The Committee considered that the supplier-proposed patient group is too narrow and excludes CKD stage 1 patients who may benefit, and that the access criteria should therefore align with the patient population from the clinical trial evidence. The Committee considered that PHARMAC could further investigate the number of New Zealand patients who may benefit from treatment with tolvaptan.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that the costs of dialysis (which would be postponed rather than not required) would generally be balanced against the cost of treatment with tolvaptan, although the rate of ADPKD progression is highly variable and some patients may have less benefit in terms of time until dialysis is required. Members considered that on average, a patient with GFR of ~45 mL per min per 1.73m<sup>2 </sup>may benefit from delaying ESRD by 4.5 years, with a total of about 12 years on tolvaptan treatment. </p><p>1.26.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee considered that tolvaptan should be funded due to the high health need of this patient group and the evidence for a benefit from tolvaptan. The Committee considered that it would like to be informed of the outcome of PHARMAC’s economic modelling and considered that PHARMAC may need to prioritise different subgroups. Members considered a recent study of changes in incidence and survival of ESRD due to PKD in Australia and New Zealand (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/28212688"" target=""_blank"">Fernando et al. Popul Health Metr. 2017;15:7</a>), transplant rates for Auckland and rates of deterioration from the REPRISE study would provide useful data for economic modelling.</p>', 'Status_History__c': 'a132P000000BAYlQAO'}, 'change': None}]",Dec 2016,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExBUAU'}, 'Id': 'a0P2P000006pExBUAU', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArEvQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExIUAU'}, 'Id': 'a0P2P000006pExIUAU', 'Event_Date__c': '2020-01-13', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jan 2020', 'Status_History__c': 'a132P000000BNciQAG'}, 'change': None}]",Dec 2016,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2020', 'fs': 'Jun 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExJUAU'}, 'Id': 'a0P2P000006pExJUAU', 'Event_Date__c': '2020-06-23', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2020', 'Status_History__c': 'a132P000000BtQxQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExKUAU'}, 'Id': 'a0P2P000006pExKUAU', 'Event_Date__c': '2021-03-11', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CfrOQAS'}, 'change': None}]",Jun 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-08-31-proposals-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/?page=3"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-08-31-proposals-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/?page=3"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExLUAU'}, 'Id': 'a0P2P000006pExLUAU', 'Event_Date__c': '2022-08-31', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-08-31-proposals-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/?page=3"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000E8cTQAS'}, 'change': None}]",Aug 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExMUAU'}, 'Id': 'a0P2P000006pExMUAU', 'Event_Date__c': '2022-09-16', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E8cYQAS'}, 'change': None}]",Sep 2022,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decisions-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decisions-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2022', 'fs': 'Nov 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pExNUAU'}, 'Id': 'a0P2P000006pExNUAU', 'Event_Date__c': '2022-11-10', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decisions-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Nov 2022', 'Status_History__c': 'a132P000000EB52QAG'}, 'change': None}]",Nov 2022,False,True
